CANbridge Pharmaceuticals has dosed the first patient in the phase 2 EMBARK study of CAN108 (maralixibat) in biliary atresia (BA) in China. The clinical trial in China is part of the larger EMBARK clinical trial in biliary atresia, which is being carried out at various sites in North America, Asia, and Europe. The multi-center randomized […]
Mirum Pharmaceuticals has secured the breakthrough therapy designation for maralixibat from the US Food and Drug Administration (FDA) for the treatment of pruritus associated with Alagille syndrome (ALGS) in patients, aged 1 year and older. The California-based biopharma company is engaged in the development and commercialization of new therapies for debilitating liver diseases. Alagille syndrome […]
Mirum Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully raised $120 million in a Series A funding round to propel the development of its lead drug, Maralixibat, aimed at treating rare cholestatic liver diseases. The round was spearheaded by New Enterprise Associates (NEA) and saw participation from other notable investors including Deerfield Management, Frazier Healthcare Partners, […]